Develops microRNA-targeting small-molecule therapeutics that inhibit miR-29 and miR-223 as multimodal tumor inhibitors. Design platform leverages high-throughput zebrafish phenotypic, molecular and pharmacokinetic data; pipelines target glioblastoma plus neurodegenerative, fibrotic, cardiovascular and psychiatric indications.